#hypertrophiccardiomyopathy #SeptalMyectomy #SeptalReductionTherapy #hipertrofikKardiyomiyopati #SeptalMiyektomi #HCM #HCOM

Dr. Tarık Kiziltan is a Professor of Cardiovascular Surgery in Adana, Turkey. Following his training, Dr. Kiziltan completed an Advanced Fellowship Program in Cardiovascular Surgery at Mayo Clinic where he was exposed to the Septal Myectomy Procedure. In this video, Dr. Kiziltan presents a patient with Hypertrophic Cardiomyopathy who underwent Septal Myectomy. Dr. Kiziltan describes his patient and gives a brief summary of the operative findings. Also, the patient describes her experiences of septal myectomy at the end of the video.
Hypertrophic Cardiomyopathy (HCM) is a genetic anomaly where the heart muscle is thicker than normal. Thick muscle tissue narrows the heart chamber (LVOTO), making the heart more difficult to squeeze. This, in turn, impairs heart function and creates signs of heart failure such as dyspnea and chest pain. Even though most patients with HCM are treated with medication, in some, this is not sufficient to make HCM patients any better. Septal Myectomy is an open-heart surgical procedure to remove excess muscle and relieve heart failure in patients with HCM. Doctors developed the Septal Myectomy Procedure at the beginning of 1960s and it has been extensively utilized for the last 6o years. Following septal myectomy, patients have the same life expectancy as their age-gender-matched counterparts in the normal population. It has also been shown that following septal myectomy, patients with previously implanted ICDs experience less electrical discharge. @prof.dr.tarkkzltan6328
www.tarikkiziltan.com/

свернуть